

February 14, 2018 06:23 PM GMT

US Economics

CPI Inflation: Higher Than Expected

Core CPI inflation surprised to the upside in January, and underlying details point to a solid reading for this month's core PCE index. Core goods prices were particularly strong, but appear to reflect—at least in part—lingering seasonality issues around the turn of the year.

Key CPI readings	Cons.	MS	% Month/Month			
			Jan-18	Dec-17	Nov-17	6m avg
Headline CPI	0.3	0.33	0.54	0.20	0.34	0.34
Core CPI	0.2	0.22	0.35	0.24	0.12	0.21
3 decimal			0.349	0.239	0.121	
1M annualized			4.3	2.9	1.5	
3M annualized			2.9	2.3	1.9	
6M annualized			2.6	2.2	2.0	
Core Goods			0.40	0.15	-0.13	0.02
Core Services			0.32	0.28	0.18	0.27
Rent & OER			0.29	0.32	0.27	0.29
Medical Services			0.56	0.15	-0.06	0.20
Core-Core Services			0.29	0.25	0.14	0.26
1M annualized			3.5	3.1	1.7	
3M annualized			2.8	2.7	2.7	
6M annualized			3.2	2.9	2.4	

MORGAN STANLEY & CO. LLC

Michel Dilmanian

ECONOMIST

Michel.Dilmanian@morganstanley.com

+1 212 761-3247

Ellen Zentner

ECONOMIST

Ellen.Zentner@morganstanley.com

+1 212 296-4882

Robert Rosener

ECONOMIST

Robert.Rosener@morganstanley.com

+1 212 296-5614

Molly Wharton

ECONOMIST

Molly.Wharton@morganstanley.com

+1 212 296-8054


For important disclosures, refer to the Disclosure Section, located at the end of this report.

Core Goods Drive Upside, But Seasonality Lingers

Core CPI surprised to the upside in January, rising 0.349% month-over-month vs. Morgan Stanley's 0.22% estimate and Bloomberg consensus of 0.2%. That result kept the year-over-year rate at 1.8%, overcoming a tough base effect from January 2017.


Upside was driven by core goods, which rose 0.40%M in January vs. 0.15% in December, the biggest increase since October 2009 and a rare respite from deflation in that category ([Exhibit 1](#) and [Exhibit 2](#)). Strength in core goods was broad-based, but apparel stood out with a 1.7% gain—the largest since 1990 amidst a general deflationary trend—that contributed 0.06pp to monthly core CPI. New vehicles prices, on the other hand, fell in January after what appears to have been a boost from the effects of last year's hurricanes.

Exhibit 1: Month-Over-Month Growth in Major Core CPI Components



Source: Bureau of Labor Statistics, Morgan Stanley Research


Exhibit 2: Contributions to Month-Over-Month Growth in Core CPI



Source: Bureau of Labor Statistics, Morgan Stanley Research

While core goods strength was broad-based, it also appears to reflect lingering seasonality issues. Since 2015, seasonally-adjusted core goods growth around the turn of the year has considerably outpaced prior and subsequent trends ([Exhibit 3](#)). Growth averaged +0.14%M in February/March 2015 vs. a prior six-month average of *negative* 0.11%M; +0.11% in January/February 2016 vs. a prior average of -0.06%; and 0.14% in December 2016 and January 2017 vs. a prior average of -0.07%. This trend appears to have continued this year, with core goods CPI rising 0.15% in December and 0.40% in January compared to a six-month moving average of -0.09% through November. **This seasonal trend points to weaker core goods prints ahead.**

Exhibit 3: Core goods prices appear to reflect lingering seasonality issues



Source: Bureau of Labor Statistics, Morgan Stanley Research

Core services inflation also picked up, rising 0.32% in January vs. 0.28% in December and contributing 0.24pp vs. 0.21pp (Exhibit 2). The acceleration in core services was driven primarily by medical services, which carries a 7% weight in core CPI and rose 0.56% vs. 0.15%. Heavily-weighted rent and owners' equivalent rent components moderated to 0.29% from 0.32%. Our forecasts see a gradual deceleration in rents weighing down on overall inflation throughout 2018, after recently elevated readings likely reflected effects of the recent hurricanes on demand for shelter. When viewed with the deceleration in new vehicle prices, **hurricane effects appear to be gradually receding from the data, clearing the way for cleaner reads on core inflation in the coming months.**

The key downside surprise in core services was in hotel prices, which dropped 2.0% and shaved 0.02pp off core CPI. Hotel prices have been particularly volatile in the CPI data, so we'd be hesitant to extrapolate January's reading forward.

Excluding the rent and medical services categories, **"core-core services"—our preferred gauge of domestic price pressures—picked up to a solid 0.29% from 0.25%**, above its six-month average of 0.26%. Core-core services has been a strong contributor to inflation since August 2017, pointing to some **momentum in underlying domestic price pressures.**

Translating CPI into PCE

Incorporating this month's CPI inputs, our preliminary forecast for January core PCE inflation is 0.25%M (0.245%, rounding down to 0.2%), **holding the year-over-year rate at 1.5%**. Headline PCE inflation should rise 0.35%M (rounding down to 0.3%), lowering the year-over-year rate to 1.6% from 1.7%.

Exhibit 4: Translating CPI into PCE

	Jan-18		Weight in:
	%M	Core CPI	Core PCE
Core Goods	0.40	25%	26%
Rent & OER	0.29	40%	18%
Medical Services (CPI)	0.56	9%	3%
Core-Core Services	0.29	26%	37%

Note: Core PCE weights don't sum to 100% given that PCE includes inputs from the PPI (not listed here). Source: Bureau of Labor Statistics, Bureau of Economic Analysis, Morgan Stanley Research.

The driver of our core PCE forecast is the core-core services gauge, which rose 0.29% in January and carries a 37% weight in core PCE. The strength in core goods will also contribute meaningfully to core PCE this month (Exhibit 4)

Rental prices and owners' equivalent rent (OER) only carry a ~18% weight in core PCE (vs. 41% in core CPI), so the relative softness in rents in the CPI has a more muted effect when translated into the PCE price index this month.

Lastly, the exceptional rise in medical services prices within the CPI hardly factors into PCE, as most PCE healthcare inputs are sourced from the Producer Price Index (to be released tomorrow, Thursday 8:30 AM ET). PCE healthcare inflation has been subdued at a ~0.1% monthly pace, as reimbursement rates have been capped by law at very little growth.

We will further hone our forecast for January core PCE inflation following the release of the PPI report tomorrow.


Measures of Trend Inflation

Overall, trend inflation appears to have firmed somewhat in recent months. The three-month annualized rate of growth in core CPI rose to 2.9% in January from 2.3% in December, and six-month annualized growth rose to 2.6% from 2.2%.

Most alternative measures of trend inflation have also been on a gradual upward path. In January, the Cleveland Fed's median CPI rose 0.05pp to 2.4%Y while the trimmed-mean CPI was flat at 1.9%Y. The Atlanta Fed's sticky CPI rose 0.05pp to 2.2%Y. The New York Fed's Underlying Inflation Gauge (UIG), which produces two separate measures of trend inflation, is slated for release this afternoon but has decelerated in recent months, from 2.3%Y in September to 2.2% in December ([Exhibit 5](#)).

More broadly, we expect core inflation to continue to be held back by longer-term factors such as technology and depressed goods prices, limiting the effects of a domestic Phillips curve (see [US Economics & Rates Strategy: What's Eating Away at Inflation?](#)). These dynamics will be pushing against a lower trade-weighted dollar path since early 2017, which should provide upward pressure. We expect the attainment of the Fed's 2% inflation goal to be a tough slog, but FOMC participants will likely look favorably upon the recent inflation data and conclude that their forecast for 2018 (1.9% core PCE 4Q/4Q) remains intact.

Exhibit 5: Measures of Trend Inflation



Source: Federal Reserve Banks of New York, Cleveland and Atlanta, Morgan Stanley Research

Disclosure Section

The information and opinions in Morgan Stanley Research were prepared by Morgan Stanley & Co. LLC, and/or Morgan Stanley C.T.V.M. S.A., and/or Morgan Stanley Mexico, Casa de Bolsa, S.A. de C.V., and/or Morgan Stanley Canada Limited. As used in this disclosure section, "Morgan Stanley" includes Morgan Stanley & Co. LLC, Morgan Stanley C.T.V.M. S.A., Morgan Stanley Mexico, Casa de Bolsa, S.A. de C.V., Morgan Stanley Canada Limited and their affiliates as necessary.

For important disclosures, stock price charts and equity rating histories regarding companies that are the subject of this report, please see the Morgan Stanley Research Disclosure Website at www.morganstanley.com/researchdisclosures, or contact your investment representative or Morgan Stanley Research at 1585 Broadway, (Attention: Research Management), New York, NY, 10036 USA.

For valuation methodology and risks associated with any recommendation, rating or price target referenced in this research report, please contact the Client Support Team as follows: US/Canada +1 800 303-2495; Hong Kong +852 2848-5999; Latin America +1 718 754-5444 (U.S.); London +44 (0)20-7425-8169; Singapore +65 6834-6860; Sydney +61 (0)2-9770-1505; Tokyo +81 (0)3-6836-9000. Alternatively you may contact your investment representative or Morgan Stanley Research at 1585 Broadway, (Attention: Research Management), New York, NY 10036 USA.

Global Research Conflict Management Policy

Morgan Stanley Research has been published in accordance with our conflict management policy, which is available at www.morganstanley.com/institutional/research/conflictolicies.

Important Disclosures

Morgan Stanley is not acting as a municipal advisor and the opinions or views contained herein are not intended to be, and do not constitute, advice within the meaning of Section 975 of the Dodd-Frank Wall Street Reform and Consumer Protection Act.

Morgan Stanley Research does not provide individually tailored investment advice. Morgan Stanley Research has been prepared without regard to the circumstances and objectives of those who receive it. Morgan Stanley recommends that investors independently evaluate particular investments and strategies, and encourages investors to seek the advice of a financial adviser. The appropriateness of an investment or strategy will depend on an investor's circumstances and objectives. The securities, instruments, or strategies discussed in Morgan Stanley Research may not be suitable for all investors, and certain investors may not be eligible to purchase or participate in some or all of them. Morgan Stanley Research is not an offer to buy or sell or the solicitation of an offer to buy or sell any security/instrument or to participate in any particular trading strategy. The value of and income from your investments may vary because of changes in interest rates, foreign exchange rates, default rates, prepayment rates, securities/instruments prices, market indexes, operational or financial conditions of companies or other factors. There may be time limitations on the exercise of options or other rights in securities/instruments transactions. Past performance is not necessarily a guide to future performance. Estimates of future performance are based on assumptions that may not be realized. If provided, and unless otherwise stated, the closing price on the cover page is that of the primary exchange for the subject company's securities/instruments.

The fixed income research analysts, strategists or economists principally responsible for the preparation of Morgan Stanley Research have received compensation based upon various factors, including quality, accuracy and value of research, firm profitability or revenues (which include fixed income trading and capital markets profitability or revenues), client feedback and competitive factors. Fixed Income Research analysts', strategists' or economists' compensation is not linked to investment banking or capital markets transactions performed by Morgan Stanley or the profitability or revenues of particular trading desks.

With the exception of information regarding Morgan Stanley, Morgan Stanley Research is based on public information. Morgan Stanley makes every effort to use reliable, comprehensive information, but we make no representation that it is accurate or complete. We have no obligation to tell you when opinions or information in Morgan Stanley Research change apart from when we intend to discontinue equity research coverage of a subject company. Facts and views presented in Morgan Stanley Research have not been reviewed by, and may not reflect information known to, professionals in other Morgan Stanley business areas, including investment banking personnel.

Morgan Stanley may make investment decisions that are inconsistent with the recommendations or views in this report.

To our readers based in Taiwan or trading in Taiwan securities/instruments: Information on securities/instruments that trade in Taiwan is distributed by Morgan Stanley Taiwan Limited ("MSTL"). Such information is for your reference only. The reader should independently evaluate the investment risks and is solely responsible for their investment decisions. Morgan Stanley Research may not be distributed to the public media or quoted or used by the public media without the express written consent of Morgan Stanley. Any non-customer reader within the scope of Article 7-1 of the Taiwan Stock Exchange Recommendation Regulations accessing and/or receiving Morgan Stanley Research is not permitted to provide Morgan Stanley Research to any third party (including but not limited to related parties, affiliated companies and any other third parties) or engage in any activities regarding Morgan Stanley Research which may create or give the appearance of creating a conflict of interest. Information on securities/instruments that do not trade in Taiwan is for informational purposes only and is not to be construed as a recommendation or a solicitation to trade in such securities/instruments. MSTL may not execute transactions for clients in these securities/instruments.

Morgan Stanley is not incorporated under PRC law and the research in relation to this report is conducted outside the PRC. Morgan Stanley Research does not constitute an offer to sell or the solicitation of an offer to buy any securities in the PRC. PRC investors shall have the relevant qualifications to invest in such securities and shall be responsible for obtaining all relevant approvals, licenses, verifications and/or registrations from the relevant governmental authorities themselves. Neither this report nor any part of it is intended as, or shall constitute, provision of any consultancy or advisory service of securities investment as defined under PRC law. Such information is provided for your reference only.

Morgan Stanley Research is disseminated in Brazil by Morgan Stanley C.T.V.M. S.A.; in Mexico by Morgan Stanley México, Casa de Bolsa, S.A. de C.V. which is regulated by Comisión Nacional Bancaria y de Valores. Paseo de los Tamarindos 90, Torre 1, Col. Bosques de las Lomas Floor 29, 05120 Mexico City; in Japan by Morgan Stanley MUFG Securities Co., Ltd. and, for Commodities related research reports only, Morgan Stanley Capital Group Japan Co., Ltd; in Hong Kong by Morgan Stanley Asia Limited (which accepts responsibility for its contents) and by Morgan Stanley Asia International Limited, Hong Kong Branch; in Singapore by Morgan Stanley Asia (Singapore) Pte. (Registration number 199206298Z) and/or Morgan Stanley Asia (Singapore) Securities Pte Ltd (Registration number 200008434H), regulated by the Monetary Authority of Singapore (which accepts legal responsibility for its contents and should be contacted with respect to any matters arising from, or in connection with, Morgan Stanley Research) and by Morgan Stanley Asia International Limited, Singapore Branch (Registration number T11FC0207F); in Australia to "wholesale clients" within the meaning of the Australian Corporations Act by Morgan Stanley Australia Limited A.B.N. 67 003 734 576, holder of Australian financial services license No. 233742, which accepts responsibility for its contents; in Australia to "wholesale clients" and "retail clients" within the meaning of the Australian Corporations Act by Morgan Stanley Wealth Management Australia Pty Ltd (A.B.N. 19 009 145 555, holder of Australian financial services license No. 240813, which accepts responsibility for its contents); in Korea by Morgan Stanley & Co International plc, Seoul Branch; in India by Morgan Stanley India Company Private Limited; in Vietnam this report is issued by Morgan Stanley Singapore Holdings; in Canada by Morgan Stanley Canada Limited, which has approved of and takes responsibility for its contents in Canada; in Germany by Morgan Stanley Bank AG, Frankfurt am Main and Morgan Stanley Private Wealth Management Limited, Niederlassung Deutschland, regulated by Bundesanstalt fuer Finanzdienstleistungsaufsicht (BaFin); in Spain by Morgan Stanley, S.V., S.A., a Morgan Stanley group company, which is supervised by the Spanish Securities Markets Commission (CNMV) and states that Morgan Stanley Research has been written and distributed in accordance with the rules of conduct applicable to financial research as established under Spanish regulations; in the United States by Morgan Stanley & Co. LLC, which accepts

responsibility for its contents. Morgan Stanley & Co. International plc, authorized by the Prudential Regulatory Authority and regulated by the Financial Conduct Authority and the Prudential Regulatory Authority, disseminates in the UK research that it has prepared, and approves solely for the purposes of section 21 of the Financial Services and Markets Act 2000, research which has been prepared by any of its affiliates. RMB Morgan Stanley Proprietary Limited is a member of the JSE Limited and regulated by the Financial Services Board in South Africa. RMB Morgan Stanley Proprietary Limited is a joint venture owned equally by Morgan Stanley International Holdings Inc. and RMB Investment Advisory (Proprietary) Limited, which is wholly owned by FirstRand Limited. The trademarks and service marks contained in Morgan Stanley Research are the property of their respective owners. Third-party data providers make no warranties or representations relating to the accuracy, completeness, or timeliness of the data they provide and shall not have liability for any damages relating to such data. The Global Industry Classification Standard (GICS) was developed by and is the exclusive property of MSCI and S&P.

Morgan Stanley Research, or any portion thereof may not be reprinted, sold or redistributed without the written consent of Morgan Stanley.

The information in Morgan Stanley Research is being communicated by Morgan Stanley & Co. International plc (DIFC Branch), regulated by the Dubai Financial Services Authority (the DFSA), and is directed at Professional Clients only, as defined by the DFSA. The financial products or financial services to which this research relates will only be made available to a customer who we are satisfied meets the regulatory criteria to be a Professional Client.

The information in Morgan Stanley Research is being communicated by Morgan Stanley & Co. International plc (QFC Branch), regulated by the Qatar Financial Centre Regulatory Authority (the QFCRA), and is directed at business customers and market counterparties only and is not intended for Retail Customers as defined by the QFCRA.

As required by the Capital Markets Board of Turkey, investment information, comments and recommendations stated here, are not within the scope of investment advisory activity. Investment advisory service is provided exclusively to persons based on their risk and income preferences by the authorized firms. Comments and recommendations stated here are general in nature. These opinions may not fit to your financial status, risk and return preferences. For this reason, to make an investment decision by relying solely to this information stated here may not bring about outcomes that fit your expectations.

© 2018 Morgan Stanley